Patents by Inventor Yaofeng Cheng

Yaofeng Cheng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL RNA TRANSCRIPT
    Publication number: 20220162610
    Abstract: An alternatively spliced intronic sequence is disclosed, the splicing of which can be induced in the presence of a small molecule, as described herein.
    Type: Application
    Filed: November 11, 2021
    Publication date: May 26, 2022
    Applicant: PTC Therapeutics, Inc.
    Inventors: Anuradha BHATTACHARYYA, Yaofeng CHENG, Kerstin Annemarie EFFENBERGER, Wencheng LI, Jana NARASIMHAN, Christopher Robert TROTTA, MARLA L. WEETALL, Matthew G. WOLL
  • Isotopically labeled triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
    Patent number: 9580422
    Abstract: Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds of formula I: or stereoisomers or pharmaceutically acceptable salts thereof, wherein R* is an isotopically labeled hydroxypropyl moiety.
    Type: Grant
    Filed: October 21, 2014
    Date of Patent: February 28, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yaofeng Cheng, Weiqi Chen, Brad D. Maxwell, Bach D. Tran, Jun Li
  • ISOTOPICALLY LABELED TRIAZOLOPYRIDINE 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS
    Publication number: 20160257680
    Abstract: Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds of formula I: or stereoisomers or pharmaceutically acceptable salts thereof, wherein R* is an isotopically labeled hydroxypropyl moiety.
    Type: Application
    Filed: October 21, 2014
    Publication date: September 8, 2016
    Inventors: Yaofeng Cheng, Weiqi Chen, Brad D. Maxwell, Bach D. Tran, Jun Li